Poseida Therapeutics, Inc., a San Diego, CA-based clinical-stage biopharmaceutical company dedicated to creating cell and gene therapeutics with the capacity to cure, closed a Series D financing round, raising $110m.
The round was led by funds advised by Fidelity Management Research Company, LLC, with participation from Adage Capital Management and Schonfeld Strategic Advisors. A number of current investors also participated in the financing.
The company intends to use the funds to continue to expand its development efforts. Led by Eric Ostertag, M.D., Ph.D., Chief Executive Officer, Poseida is a clinical-stage biopharmaceutical company dedicated to utilizing a proprietary gene engineering platform technologies to create next generation cell and gene therapeutics. It is developing a broad portfolio of product candidates in a variety of indications based on its core proprietary platforms, including a non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies.
The portfolio includes allogeneic and autologous CAR-T product candidates in both hematological and solid tumor oncology indications, as well as liver-directed gene therapy programs in orphan genetic diseases.